Dry Powder Inhalers: Annual Conference 2018
In-Person Event
Jun 20 - 21, 2018
London, England, GB
OVERVIEW
Dry Powder Inhalers: Annual Conference is organized by Management Forum (Mf) Ltd and will be held during Jun 20 - 21, 2018 at The Rembrandt Hotel, London, England, United Kingdom.
The target audience for this medical event is Respiratory drug development, Inhalation product development, Device engineering, Formulation development, Scientific research, Medical marketing, Marketing and Business development.
Course Description:
The second generation of DPIs have become either established on the market or are a significant way along the approval process, these have been a great success story in improving inhaled drug delivery. However, we now have to tackle the technical and regulatory issues with ‘generic’ inhalers and their approval. The development of triple therapies is well underway, these bring about their own challenges of formulation and bioequivalence. Amazingly, new DPIs are still being created, with some moving into development programs. Further, one of the areas where many studies and recent guidance has been applied is in considering the patient use, compliance and human factors associated with DPIs. These linked topics are creating a whole new area that requires better understanding during product development and associated studies.
This annual conference aims to: address many of the issues around generic inhalers, provide case studies of bioequivalence testing, focus on the difficult formulation challenges and the strategies used so that they may be overcome and to discuss in-depth patient and human factor issues when developing a DPI to gain regulatory approval.
Tickets:
EUR 2,099.00
USD 2,338.00
Additional details will be posted as soon as they are available.
The target audience for this medical event is Respiratory drug development, Inhalation product development, Device engineering, Formulation development, Scientific research, Medical marketing, Marketing and Business development.
Course Description:
The second generation of DPIs have become either established on the market or are a significant way along the approval process, these have been a great success story in improving inhaled drug delivery. However, we now have to tackle the technical and regulatory issues with ‘generic’ inhalers and their approval. The development of triple therapies is well underway, these bring about their own challenges of formulation and bioequivalence. Amazingly, new DPIs are still being created, with some moving into development programs. Further, one of the areas where many studies and recent guidance has been applied is in considering the patient use, compliance and human factors associated with DPIs. These linked topics are creating a whole new area that requires better understanding during product development and associated studies.
This annual conference aims to: address many of the issues around generic inhalers, provide case studies of bioequivalence testing, focus on the difficult formulation challenges and the strategies used so that they may be overcome and to discuss in-depth patient and human factor issues when developing a DPI to gain regulatory approval.
Tickets:
EUR 2,099.00
USD 2,338.00
Additional details will be posted as soon as they are available.
KEY DATES
20 Jun, 2018
Event Start Date
21 Jun, 2018
Event End Date
SPECIALITIES
Healthcare ManagementSUGGESTED HOTELS
CONFERENCE VENUE
The Rembrandt HotelRELATED CONFERENCES & LIVE WEBINARS
Quick Links